CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-19-0608
Abstract: Genetic screens identify the kinase CAMK1D as a regulator of antitumor immune resistance in anti–PD-L1–refractory cancer. CAMK1D activation in tumor cells, through CTL stimulation of the Fas receptor, inhibits caspase-mediated cell death of anti–PD-L1–refractory tumors.… read more here.
Keywords: immune resistance; resistance; camk1d; tumor ... See more keywords